Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Abbott Labs Announces $184 Million In Settlements

By Pharmaceutical Processing | November 21, 2008

NORTH CHICAGO, Ill. (AP) _ Pharmaceutical and medical products maker Abbott Laboratories Inc. has announced settlements totaling about $184 million for a federal court case involving class action claims over its popular cholesterol medication TriCor. The settlement resolves allegations by drug wholesalers and generic drugmakers that Abbott sought to block competition for cheaper, generic versions of its blockbuster drug TriCor. The plaintiffs, which included generic firm Teva Pharmaceuticals, said Abbott made minor changes to TriCor’s formulation to prevent generic versions from being launched, allowing the company to charge monopoly prices. A similar lawsuit brought by more than a dozen state governments is awaiting trial in the same U.S. District Court in Wilmington. A company spokesman said Thursday’s announcement resolves the bulk of the litigation connected with Tricor. The company did not admit to any wrongdoing. “We continue to believe our actions were lawful and we reached these settlements to avoid the uncertainty of a trial outcome,” an Abbott spokesperson said. The company said in a brief statement it would treat the settlement payments as a specified item in the fourth quarter. TriCor accounted for more than $1 billion of Abbott’s sales last year. Abbott had total revenue of $25.9 billion in 2007.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE